New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 18, 2014
13:19 EDTRGDXResponse Genetics to serve as molecular screening center for ALCHEMIST
Response Genetics (RGDX) announced that it has been awarded a multi-million dollar research subcontract to support the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials, or ALCHEMIST. ALCHEMIST consists of 3 integrated precision medicine trials that are being implemented through the National Clinical Trials Network of the National Cancer Institute, or NCI, a screening trial and two associated treatment trials. The research subcontract was awarded by Leidos Biomedical Research (LDOS).
News For RGDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for RGDX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use